Adamas Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Adamas Pharma (ADMS) Prices 2.5M Shares at $23
January 6, 2016 10:37 PM ESTAdamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $23.00 per share. Adamas also granted the underwriters a 30-day option to acquire an additional 375,000 shares from... More
Adamas Pharma (ADMS) Announces Issuance of Markman Ruling in Namenda XR Suit
January 6, 2016 6:24 AM ESTAdamas Pharma (NASDAQ: ADMS) disclosed the following on Wednesday:
On January 5, 2016, the Delaware District Court issued a Markman ruling in the litigation that we, Forest Laboratories, Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH (together Merz) filed against several companies that submitted... More
